Novartis reports positive clinical trial data for migraine therapy

Novartis has announced new clinical trial data showing the benefits its drug erenumab can offer in the treatment of people with migraines that have failed to respond to other therapies.

Data from the phase IIIb LIBERTY study has demonstrated the efficacy and safety of erenumab in patients with episodic migraine who had experienced two to four previous preventive treatment failures, due to lack of efficacy or intolerable side effects.

The study met its primary endpoint, with significantly more patients taking erenumab experiencing at least a 50 percent reduction from baseline in monthly migraine days compared to placebo, while also meeting all secondary endpoints, including a reduced need for acute medication and improvement in physical function scores.

This represents the first migraine prevention trial of its kind conducted specifically in patients who have tried multiple therapies without success, which is important given the strong need for additional treatment options among this patient group.

Danny Bar-Zohar, global head of neuroscience development for Novartis, said: "The results add to the consistent body of evidence for erenumab across the full spectrum of migraine patients, from those trying preventive medication for the first time through to those who have failed multiple therapies and have been suffering for years."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.